ClinicalTrials.gg
CompletedNCT01764594Updated Jul 16, 2015

Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

A Phase 1 interventional study of CDP7657 and Placebo in Immune System Diseases, Autoimmune Diseases and Lupus Erythematosus, Systemic, sponsored by UCB Pharma. Completed at 21 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-07-16.

Primary conditionLupus Erythematosus, SystemicRegistry: Immune System DiseasesReclassifiedWhy we changed it
Registry
Immune System Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lupus Erythematosus, Systemic
Why
  1. The study's listed conditions name Lupus Erythematosus, Systemic, a narrower term within Immune System Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Lupus Erythematosus, Systemic by UCB S.A. — 4 open to participants now, 4 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · UCB S.A..

Enrollment
17th of 21
24 · median 54
Started
2013
the only one that year
Phase 1
5 of 21
2 open now
Registered
14th of 21
by date

Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., this one is the 17th largest by enrollment, is the only one that started in 2013, is one of 5 in phase 1, and was the 14th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 21 studies in Lupus Erythematosus, Systemic by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Lupus Erythematosus, Systemic by UCB S.A., or all of them as a file.
02

Study summary

To evaluate safety, tolerability pharmacokinetics and immunogenicity of CDP7657.

03

Conditions studied

  • Immune System Diseases
  • Autoimmune Diseases
  • Lupus Erythematosus, Systemic
  • Skin and Connective Tissue Diseases
  • Connective Tissue Disease

Keywords

  • Lupus
  • SLE
04

In context

Lupus Erythematosus, Systemic Reclassified

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

This study's enrollment of 24 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.

Compared within Lupus Erythematosus, Systemic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Immune System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Systemic Lupus Erythematosus (SLE)

Exclusion criteria

Exclusion Criteria:

  • Severe neuropsychiatric or severe renal Systemic Lupus Erythematosus (SLE)
  • History of chronic, recurrent, or recent severe infection
  • Significant hematologic abnormalities
  • History of cancer, heart failure, renal disease, liver disease or other serious illness
06

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    CDP7657

    CDP7657 100 mg/ ml solution 30 mg/ kg initial dose 15 mg/ kg every other week 10 weeks

    Biological: CDP7657

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • BiologicalCDP7657

    CDP7657 100 mg/ ml solution 30 mg/ kg initial dose 15 mg/ kg every other week 10 weeks

  • OtherPlacebo

    Placebo comparator

07

What researchers measure

Primary outcomes

  1. Percentage of subjects with at least one Treatment-emergent Adverse Event (TEAE) during the study

    Time frame: 0 - 28 Weeks

  2. Percentage of subjects who withdrew due to an Treatment-emergent Adverse Event (TEAE) during the study

    Time frame: 0 - 28 Weeks

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: 0 - 28 Weeks

  2. Predose plasma concentration (Ctrough)

    Time frame: 0 - 28 Weeks

  3. Area under the concentration-time curve over the dosing interval (AUCτ)

    Time frame: 0 - 28 Weeks

08

Study locations

21 sites
  • 102
    Brussels, Belgium
  • 101
    Leuven, Belgium
  • 203
    Plovidv, Bulgaria
  • 201
    Sofia, Bulgaria
  • 202
    Sofia, Bulgaria
  • 301
    Berlin, Germany
  • 303
    Erlangen, Germany
  • 305
    Frankfurt, Germany
  • 306
    Greifswald, Germany
  • 304
    Hannover, Germany
  • 302
    Kiel, Germany
  • 501
    Krakow, Poland
  • 503
    Wroclaw, Poland
  • 601
    Bucharest, Romania
  • 602
    Cluj, Romania
  • 701
    Moscow, Russian Federation
  • 702
    Yaroslavl, Russian Federation
  • 401
    Hospitalet Del Llobregat, Spain
  • 402
    Santiago de Compostela, Spain
  • 404
    Sevilla, Spain
  • 405
    Sevilla, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2013
First posted
Jan 9, 2013
Start
Jan 2013
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Last update
Jul 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01764594
Lead sponsor
UCB Pharma
Collaborators
Biogen
Responsible party
Sponsor
First posted
Jan 9, 2013
Start date
Jan 2013
Primary completion
Aug 2014
Completion
Aug 2014
Last update
Jul 16, 2015

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapirolizumab pegol

Start the discussion